机构：[1]Guangzhou Univ Chinese Med, Res Ctr Integrat Med, Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China广东省中医院[2]Guangzhou Univ Chinese Med, Integrat Res Lab Breast Canc, Discipline Integrated Chinese & Western Med, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China广东省中医院
出处：
ISSN：
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81703749, 81573651, 81703764]; Guangdong Science and Technology Department [2016A030306025]; Pearl River S&T Nova Program of Guangzhou [201506010098]; Combined Scientific Project - Guangdong Provincial Science and Technology Agency; Guangdong Provincial Academy of Traditional Chinese Medicine [2014A020221047]; Guangdong High-level University Construction Project [A1-AFD018161Z1510, A1-AFD018171Z11102, A1-AFD018171Z11101]; Guangdong High-level Personnel of Special Support Program [A1-3002-16-111-003]; Guangdong traditional Chinese medicine bureau project [20181132, 20182044]; Post-doctoral Science Foundation of ChinaChina Postdoctoral Science Foundation [2017M612644, 2017M622669]; PhD Start-up Fund of Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2017A030310213]
第一作者机构：[1]Guangzhou Univ Chinese Med, Res Ctr Integrat Med, Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Wang N.,Wang Z. Y.,Yang B. W.,et al.Identification of caveolin-1 as key mediator of Ai Du Qing formula enhancing breast cancer chemosensitivity by network pharmacology[J].BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY.2018,123:33-33.
APA：
Wang, N.,Wang, Z. Y.,Yang, B. W.,Wang, S. Q.,Zheng, Y. F....&Zhuang, D. X..(2018).Identification of caveolin-1 as key mediator of Ai Du Qing formula enhancing breast cancer chemosensitivity by network pharmacology.BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY,123,
MLA：
Wang, N.,et al."Identification of caveolin-1 as key mediator of Ai Du Qing formula enhancing breast cancer chemosensitivity by network pharmacology".BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 123.(2018):33-33
